Stockscreener 앱 받기
0.2933
7.68%
-0.0244
시간 외 거래:
.31
0.0167
+5.69%
전일 마감가:
$0.3177
열려 있는:
$0.308
하루 거래량:
1.91M
Relative Volume:
3.09
시가총액:
$4.71M
수익:
-
순이익/손실:
$-8.74M
주가수익비율:
-0.1431
EPS:
-2.05
순현금흐름:
$-8.25M
1주 성능:
+11.95%
1개월 성능:
+20.60%
6개월 성능:
-83.04%
1년 성능:
-75.71%
1일 변동 폭
$0.29
$0.3296
1주일 범위
$0.26
$0.39
52주 변동 폭
$0.2012
$4.95
Glucotrack Inc Stock (GCTK) Company Profile
명칭
Glucotrack Inc
전화
972 (8) 675-7878
주소
301 RT 17 NORTH, RUTHERFORD
GCTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.2933 | 4.71M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Glucotrack Inc 주식(GCTK)의 최신 뉴스
SABBY MANAGEMENT, LLC Acquires Significant Stake in GlucoTrack I - GuruFocus.com
SABBY MANAGEMENT, LLC Acquires Significant Stake in GlucoTrack Inc - GuruFocus.com
Glucotrack Receives Notice from Nasdaq Regarding Bid Price Rule Compliance**Washington, D.C., December 31, 2024 – Glucotrack, Inc. (NASDAQ: GCTK) recently received notification from the Nasdaq Stock Market LLC (“Nasdaq”) concerning its bid price f - Defense World
Glucotrack inks sales agreement for $8.23M stock offering - Investing.com
Glucotrack inks sales agreement for $8.23M stock offering By Investing.com - Investing.com UK
GCTK Stock Plummets to 52-Week Low at $0.21 Amid Market Struggles - Investing.com Australia
Glucotrack Initiates Human Clinical Trials for Innovative Implantable Continuous Blood Glucose Monitor - Citybuzz
Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor - Nasdaq
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor - Drug Delivery Business News
Glucotrack Begins Enrollment for Long-term Implantable CGM Study - MD+DI
GlucoTrack Begins Clinical Study of Implantable Glucose Monitor - TipRanks
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR - The Manila Times
Glucotrack Launches Clinical Trial for 3-Year Implantable Glucose Monitor - StockTitan
Harvard Bioscience (HBIO) Stock Surges Amid Positive Analyst Rat - GuruFocus.com
GCTK stock touches 52-week low at $0.23 amid market challenges - Investing.com Australia
GCTK stock touches 52-week low at $0.23 amid market challenges By Investing.com - Investing.com South Africa
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - MSN
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - MSN
Glucotrack enters material agreements following public offering - Investing.com India
Glucotrack enters material agreements following public offering By Investing.com - Investing.com UK
Glucotrack announces pricing of $10M public offering - MSN
West Pharmaceutical Services (WST) Stock Drops Amid Sector Downt - GuruFocus.com
GlucoTrack Inc. (GCTK) Quarterly 10-Q Report - Quartzy
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt - The Manila Times
GlucoTrack Completes Funding to Enhance Financial Stability - TipRanks
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD) - The Manila Times
Glucotrack Secures $10M Through Public Offering, Converts $4M Debt to Equity | GCTK Stock News - StockTitan
STXS Stock Drops 5% Despite Strong Buy Ratings from Analysts - GuruFocus.com
Glucotrack announces $10 million public offering By Investing.com - Investing.com Canada
GCTK stock touches 52-week low at $0.42 amid market fluctuations - Investing.com Australia
500: Something went wrong - Investing.com Canada
S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results - Benzinga
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings - Benzinga
U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
US Stocks Mixed; Inflation Rate Increases In October - Benzinga
GlucoTrack prices 7.2M shares at $1.39 in public offering - TipRanks
Glucotrack announces $10 million public offering - Investing.com
Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering - The Manila Times
Fogo de Chão Launches Pro-Athlete 'Meat & Greet” Event Series With National Sports Teams - The Manila Times
Glucotrack (GCTK) Launches $10M Public Offering, Plans Note Conversion Deal | GCTK Stock News - StockTitan
Harvard Bioscience (HBIO) Stock Dips Amid Market Volatility - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.65% - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.66% - MSN
AtriCure (ATRC) Stock Surges Over 5% Amid Market Volatility - GuruFocus.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.67% - MSN
GlucoTrack (NASDAQ:GCTK) to Present Continuous Blood Glucose Monitor at 2024 BioFuture Meeting** - Defense World
Say Goodbye To Finger Pricks! Glucotrack($GCTK)’s Long-Lasting Glucose Monitor Is Here - MSN
GCTKGlucoTrack, Inc. Latest Stock News & Market Updates - StockTitan
GlucoTrack to Unveil Implantable Glucose Monitor at BioFuture - TipRanks
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE - The Manila Times
Glucotrack Inc (GCTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
0.11%
자본화:
|
볼륨(24시간):